89Zr-Trastuzumab PET/CT Imaging of HER2-Positive Breast Cancer for Predicting Pathological Complete Response after Neoadjuvant Systemic Therapy: A Feasibility Study

D.G.J. Linders*, M.M. Deken, M.A. van Dam, M.N.J.M. Wasser, E.M.C. Voormolen, J.R. Kroep, G.A.M.S. van Dongen, D. Vugts, H.M. Oosterkamp, M.E. Straver, C.J.H. van de Velde, D. Cohen, P. Dibbets-Schneider, F.H.P. van Velden, L.M. Pereira Arias-Bouda, A.L. Vahrmeijer, G.J. Liefers, L.F. de Geus-Oei, D.E. Hilling

*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

26 Downloads (Pure)

Fingerprint

Dive into the research topics of '89Zr-Trastuzumab PET/CT Imaging of HER2-Positive Breast Cancer for Predicting Pathological Complete Response after Neoadjuvant Systemic Therapy: A Feasibility Study'. Together they form a unique fingerprint.

Medicine and Dentistry